NuVasive (NUVA) lowers its Q3 outlook, saying it anticipates revenue to be around $147M, below earlier expectations for flat sequential revenue growth. The company experienced unusually high account churn related primarily to the growth of surgeon participation in physician-owned distributorships and to increasingly aggressive tactics from its competitors. Additionally, it heard from many surgeon customers of "increased delays and denials from insurance payers", and will provide revised full year guidance on its October 29th earnings conference call. Shares -21% AH.
NuVasive (NUVA) lowers its Q3 outlook, saying it anticipates revenue to be around $147M, below...
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs